Cargando…
SARS CoV-2 vaccine AND rituximab. Comment on: “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response” by Verhoeven Joint Bone Spine. 2021;88:105258
Autores principales: | Mungmunpuntipantip, Rujittika, Wiwanitkit, Viroj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de rhumatologie. Published by Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480129/ https://www.ncbi.nlm.nih.gov/pubmed/34600149 http://dx.doi.org/10.1016/j.jbspin.2021.105281 |
Ejemplares similares
-
Comment on: “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response” by Verhoeven et al. Joint Bone Spine 2021;88:105258
por: De Marchi, Ginevra, et al.
Publicado: (2022) -
Comment on “immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab”
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022) -
Answer to Mungmunpuntipantip et al. “SARS CoV-2 vaccine AND rituximab” Joint Bone Spine 2021;88:105281
por: Verhoeven, Frank, et al.
Publicado: (2022) -
Hemophagocytic lymphohistiocytosis and SARS-CoV-2 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022) -
Subacute thyroiditis and different SARS-CoV-2 vaccine
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)